Posted by Michael Wonder on 06 Dec 2018
Ultragenyx and Kyowa Kirin announce Health Canada approval of Crysvita (burosumab injection) for the treatment of X–linked hypophosphataemia in adults and children
6 December 2018 - First approved treatment for XLH in Canada that targets the underlying cause of this rare, hereditary, lifelong disease.
Ultragenyx and Kyowa Hakko Kirin and Kyowa Kirin International today announced that Crysvita (burosumab injection) has been approved by Health Canada for the treatment of X-linked hypophosphataemia (XLH) in adult and paediatric patients one year of age and older.
The product is expected to be available for prescription to Canadian patients in early 2019. XLH is a rare, hereditary, lifelong disease.
